Section Arrow
NNVC.NYSE-M
- NanoViricides
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 1.21
-0.06 (-4.72%)
Day High 
1.3 
Prev. Close
1.27 
1-M High
1.37 
Volume 
105.49K 
Bid
1.19
Ask
1.2
Day Low
1.19 
Open
1.26 
1-M Low
1.11 
Market Cap 
19.86M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.28 
20-SMA 1.27 
50-SMA 1.25 
52-W High 3.59 
52-W Low 1.0297 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.71/-0.21
Enterprise Value
19.86M
Balance Sheet
Book Value Per Share
0.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in theapplication of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.